Literature DB >> 25583772

Neuroendocrine tumors, version 1.2015.

Matthew H Kulke, Manisha H Shah, Al B Benson, Emily Bergsland, Jordan D Berlin, Lawrence S Blaszkowsky, Lyska Emerson, Paul F Engstrom, Paul Fanta, Thomas Giordano, Whitney S Goldner, Thorvardur R Halfdanarson, Martin J Heslin, Fouad Kandeel, Pamela L Kunz, Boris W Kuvshinoff, Christopher Lieu, Jeffrey F Moley, Gitonga Munene, Venu G Pillarisetty, Leonard Saltz, Julie Ann Sosa, Jonathan R Strosberg, Jean-Nicolas Vauthey, Christopher Wolfgang, James C Yao, Jennifer Burns, Deborah Freedman-Cass.   

Abstract

Neuroendocrine tumors (NETs) comprise a broad family of tumors that may or may not be associated with symptoms attributable to hormonal hypersecretion. The NCCN Clinical Practice Guidelines in Oncology for Neuroendocrine Tumors discuss the diagnosis and management of both sporadic and hereditary NETs. This selection from the guidelines focuses on sporadic NETs of the pancreas, gastrointestinal tract, lung, and thymus.
Copyright © 2015 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Year:  2015        PMID: 25583772     DOI: 10.6004/jnccn.2015.0011

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  114 in total

1.  The efficacy of (177)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis.

Authors:  Seong-Jang Kim; Kyoungjune Pak; Phillip J Koo; Jennifer J Kwak; Samuel Chang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-09       Impact factor: 9.236

2.  Further Classification for Node-Positive Gastric Neuroendocrine Neoplasms.

Authors:  Linda M Pak; Tingsong Yang; Jiping Wang
Journal:  J Gastrointest Surg       Date:  2018-06-27       Impact factor: 3.452

3.  Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors.

Authors:  Chan Shen; Ying Xu; Arvind Dasari; Ya-Chen Tina Shih; James C Yao
Journal:  Oncologist       Date:  2016-02-24

Review 4.  Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies.

Authors:  Gitta Boons; Timon Vandamme; Marc Peeters; Guy Van Camp; Ken Op de Beeck
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

5.  Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases.

Authors:  Arvind Dasari; Kathan Mehta; Lauren A Byers; Halfdan Sorbye; James C Yao
Journal:  Cancer       Date:  2017-12-06       Impact factor: 6.860

6.  Duodenal and Ampullary Carcinoid Tumors: Size Predicts Necessity for Lymphadenectomy.

Authors:  Epameinondas Dogeas; John L Cameron; Cristopher L Wolfgang; Kenzo Hirose; Ralph H Hruban; Martin A Makary; Timothy A Pawlik; Michael A Choti
Journal:  J Gastrointest Surg       Date:  2017-05-17       Impact factor: 3.452

7.  Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.

Authors:  Joo Young Kim; Jacqueline A Brosnan-Cashman; Soyeon An; Sung Joo Kim; Ki-Byung Song; Min-Sun Kim; Mi-Ju Kim; Dae Wook Hwang; Alan K Meeker; Eunsil Yu; Song Cheol Kim; Ralph H Hruban; Christopher M Heaphy; Seung-Mo Hong
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

Review 8.  Management of gastric and duodenal neuroendocrine tumors.

Authors:  Yuichi Sato; Satoru Hashimoto; Ken-Ichi Mizuno; Manabu Takeuchi; Shuji Terai
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

9.  Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors.

Authors:  Sally C Lau; Omar Abdel-Rahman; Winson Y Cheung
Journal:  Med Oncol       Date:  2018-08-04       Impact factor: 3.064

Review 10.  Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Jessica E Maxwell; Thomas M O'Dorisio; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2015-10-31       Impact factor: 3.495

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.